Internalization and Recycling of the HER2 Receptor on Human Breast Adenocarcinoma Cells Treated with Targeted

O N Shilova1, G M Proshkina1, E N Lebedenko1

  • 1Shemyakin/Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Miklukho-Maklaya Str., 16/10, Moscow, 117997, Russia.

Acta Naturae
|October 21, 2015
PubMed

Insights

Researchers developed a phototoxic protein, DARPin-miniSOG, that targets and enters HER2-positive breast cancer cells. This protein

Area of Science:

  • Biomedicine
  • Molecular Biology
  • Cancer Research

Background:

  • Developing targeted cancer therapies is crucial.
  • High-affinity protein compounds can selectively destroy cancer cells.
  • HER2 overexpression is common in breast adenocarcinomas.

Purpose of the Study:

  • To evaluate the recombinant phototoxic protein DARPin-miniSOG.
  • To assess its interaction with HER2-positive breast cancer cells.
  • To understand its potential in cancer treatment.

Main Methods:

  • Designing and evaluating high-affinity protein compounds.
  • Utilizing recombinant phototoxic protein DARPin-miniSOG.
  • Studying interactions with breast adenocarcinoma cells overexpressing HER2.

Main Results:

  • DARPin-miniSOG specifically binds to HER2.
  • The protein undergoes internalization into cancer cells.
  • Slow recycling of DARPin-miniSOG to the cell membrane was observed.

Conclusions:

  • DARPin-miniSOG shows specific binding and internalization in HER2-positive cancer cells.
  • Understanding DARPin-miniSOG's role in HER2 internalization is key.
  • This phototoxic protein holds promise for treating HER2-positive cancers.